The clinical stage biopharmaceutical firm Atossa Therapeutics (NASDAQ:ATOS) has been in focus among investors in recent times due to its work on both COVID 19 and cancer treatments.
In the first half of the year, the Atossa stock had delivered considerable gains to investors but in the past three months, the trend has reversed in a big way and the stock has lost around 50%. However, it is also true that it might also be the right opportunity for new investors to get into the stock and Edward Moo, an analyst at Ascendiant has listed some of the positives with regards to Atossa.
In this regard, Woo noted that in the past three quarters Atossa raised as much as $142 million by way of stock offerings and that money is going to be enough to keep the company running up until 2021. On the other hand, the company’s inhalation therapy product for Covid 19 patients named AT H201 is another factor to keep in mind. Clinical trials for it are going to start soon in Australia.
The Phase 1 clinical trials for the nasal spray AT 301 for mild Covid 19 patients have also been completed. Last but not the least, its breast cancer product Endoxifen is also a factor that investors ought to keep in mind when considering the Atossa stock.
